Compare Direxion Daily Semiconductor Bear 3X Shares (SOXS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bear 3X Shares vs Spyre Therapeutics Inc. Common Stock — how do they compare? Direxion Daily Semiconductor Bear 3X Shares trades at $45.38 (market cap $2.44B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 3.1× Direxion Daily Semiconductor Bear 3X Shares's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Direxion Daily Semiconductor Bear 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bear 3X Shares for 11 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SOXS | SYRE | |
|---|---|---|
Market Cap | $2.44B | $7.52B |
Volume | 88,729,812 | 1,441,031 |
Sector | Leveraged / Inverse | Health |
52-Week High | $944.00 | $108.92 |
52-Week Low | $29.62 | $22.18 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXS trades at $37.42, up 0.48% with a mixed technical outlook showing bullish overall signals but bearish moving averages. The ETF faces significant volatility as a 3x leveraged inverse semiconductor fund, with recent performance driven by semiconductor sector weakness. Recent news highlights ongoing challenges in the semiconductor space, including Nvidia's China exposure and competitive pressures.
As a tactical inverse ETF, SOXS offers short-term hedging potential against semiconductor declines but carries substantial decay risks for long-term holders. The fund's structure makes it unsuitable for buy-and-hold strategies, with success dependent on accurately timing semiconductor sector downturns amid persistent AI demand.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
